← Library

Desmopressin (DDAVP)

Peptide Index
FDA ApprovedSince 1978
Also known as DDAVP, Stimate, Nocdurna

Function

Primary
Diabetes Insipidus · vWD Type I · Nocturia
Mechanism
V2 receptor agonist — increases renal water reabsorption via AQP2 upregulation; promotes vWF and Factor VIII release.
Evidence
Clinical RCT (Phase III)
Research
Multiple Phase III trials

Dosing

Range
0.1–0.4 mg/day (oral); 10–40 mcg/day (intranasal)
Frequency
Daily to BID
Route
Oral · Intranasal · Intravenous

Cycling

Continuous; fluid restriction required.

Benefits

  • ·Controls polyuria in central DI
  • ·Reduces nocturia frequency
  • ·Hemostasis in mild vWD/hemophilia A

Risks

  • ·Hyponatremia (potentially fatal)
  • ·Seizures in children
  • ·Headache
  • ·Fluid retention

Contraindications

  • ·Hyponatremia history
  • ·Moderate–severe renal impairment
  • ·SIADH
  • ·Heart failure with fluid overload

Regulatory

FDA-Approved Rx

Cited Works

  1. Sanofi. DDAVP (desmopressin) Prescribing Information.
View full reference repository →
Sign in to save favorites & stacks